Advanced Biomed Valuation Analysis

Stocks . USA . 
Stock . Advanced Biomed Common
ADVB Stock   7.20  0.42  6.19%   
Advanced Biomed is priced without meaningful earnings support, reflecting the current earnings and balance-sheet profile. Advanced Biomed's market cap stands at 11.1 M, with enterprise value at 6 M. That works out to roughly 0.91 times book value.
Key valuation drivers for Advanced Biomed include:
 Price Book
0.91
 Enterprise Value
6.03 million
 Trailing PE
1.93
Below Model Estimate
Today
7.20
The intrinsic value estimate for Advanced Biomed Common is based on a 3 months horizon. Lack of a positive P/E ratio suggests inconsistent earnings, which introduces uncertainty into valuation. Extending the time horizon generally improves valuation stability.
6.48
Downside
73.37
Intrinsic Value
82.61
Upside
Current intrinsic value estimate framed by downside and upside probability thresholds.
Target Odds

Advanced Biomed Cash

$3.51 billion
Cash stood at $3.34 billion as of December 31, 2025.

Valuation Framework, Methodology & Assumptions

Advanced Biomed is a micro-cap equity in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care categories. Capital allocation discipline strengthens intrinsic value context. For Advanced Biomed, enterprise value (TTM) of 6.03 million anchors the current valuation read, with P/B of 0.91 adding context.

Advanced Biomed Common inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Valuation outputs are model-derived and depend on published assumptions and reference inputs.

The analysis above is generated by quantitative models and is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an endorsement to buy or sell any security. All investing involves risk, including the possible loss of principal. Consult a qualified financial advisor before making investment decisions. See our Terms of Use for full details.

Financial data referenced in this analysis is derived from publicly available SEC filings, audited financial statements, and third-party market data providers. The intrinsic value estimate is generated by Macroaxis quantitative models that incorporate fundamental analysis, technical indicators, and risk metrics.

The methodology combines multiple analytical inputs:

  • Fundamental analysis - financial statements, profitability ratios, debt structure, and cash flow metrics sourced from SEC filings and public financial reports
  • Technical indicators - historical price patterns, momentum signals, and volatility measures
  • Risk assessment - probability of bankruptcy models, market risk metrics, and downside scenario analysis
  • Peer comparison - relative valuation against industry peers using standardized multiples

Model outputs are refreshed periodically as new financial data becomes available. Past model performance is not indicative of future results. The intrinsic value estimate reflects a point-in-time calculation and should be considered alongside other research and professional advice.

Data sourced from SEC filings (EDGAR), public financial statements, and market data providers.

Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board

Advanced Biomed Current Valuation Indicators

Valuation of Advanced Biomed Common is strongest when several lenses are used together: market cap, enterprise value. revenue, and cash-flow durability. The business currently sits in the Healthcare sector and the Diagnostics & Research industry. Current pricing suggests the market is discounting specific expectations about growth trajectory, margin stability, and capital allocation. Reported values are derived from company filings, audited financial statements, and market data, and are standardized within Macroaxis quantitative models for consistency. Model outputs reflect a point-in-time estimate based on available data and assumptions and should be interpreted alongside changes in operating performance, market conditions, and forward expectations.
Book Value Per Share
Net Current Asset Value
Tangible Asset Value
Tangible Book Value Per Share

Popular Tools for Advanced Biomed Stock analysis

Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.